» Articles » PMID: 37798868

Erythrocytic α-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease

Overview
Journal Mov Disord
Date 2023 Oct 6
PMID 37798868
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Progressive spreading of α-synuclein via gut-brain axis has been hypothesized in the pathogenesis of Parkinson's disease (PD). However, the source of seeding-capable α-synuclein in the gastrointestinal tract (GIT) has not been fully investigated. Additionally, the mechanism by which the GIT microbiome contributes to PD pathogenesis remains to be characterized.

Objectives: We aimed to investigate whether blood-derived α-synuclein might contribute to PD pathology via a gut-driven pathway and involve GIT microbiota.

Methods: The GIT expression of α-synuclein and the transmission of extracellular vesicles (EVs) derived from erythrocytes/red blood cells (RBCs), with their cargo α-synuclein, to the GIT were explored with various methods, including radioactive labeling of RBC-EVs and direct analysis of the transfer of α-synuclein protein. The potential role of microbiota on the EVs transmission was further investigated by administering butyrate, the short-chain fatty acids produced by gut microbiota and studying mice with different α-synuclein genotypes.

Results: This study demonstrated that RBC-EVs can effectively transport α-synuclein to the GIT in a region-dependent manner, along with variations closely associated with regional differences in the expression of gut-vascular barrier markers. The investigation further revealed that the infiltration of α-synuclein into the GIT was influenced significantly by butyrate and α-synuclein genotypes, which may also affect the GIT microbiome directly.

Conclusion: By demonstrating the transportation of α-synuclein through RBC-EVs to the GIT, and its potential association with gut-vascular barrier markers and gut microbiome, this work highlights a potential mechanism by which RBC α-synuclein may impact PD initiation and/or progression. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Citing Articles

Peripheral proteinopathy in neurodegenerative diseases.

Xu B, Lei X, Yang Y, Yu J, Chen J, Xu Z Transl Neurodegener. 2025; 14(1):2.

PMID: 39819742 PMC: 11737199. DOI: 10.1186/s40035-024-00461-6.


Radiation-Induced Brain Injury: Mechanistic Insights and the Promise of Gut-Brain Axis Therapies.

Li M, Tong F, Wu B, Dong X Brain Sci. 2025; 14(12.

PMID: 39766494 PMC: 11674909. DOI: 10.3390/brainsci14121295.


Brain-Periphery Axes: The Potential Role of Extracellular Vesicles-Delivered miRNAs.

DAmico G, Carista A, Manna O, Paladino L, Picone D, Sarullo S Biology (Basel). 2025; 13(12.

PMID: 39765723 PMC: 11673379. DOI: 10.3390/biology13121056.


Proton pump inhibitors reduce chemotherapeutic hepatotoxicity and enhance hepatic uptake and accumulation of drug-loaded extracellular vesicles.

Li M, Yuan W, Kong X, Wu H, Cai Z, Zhu W Sci Rep. 2024; 14(1):28163.

PMID: 39548145 PMC: 11568174. DOI: 10.1038/s41598-024-75775-6.


The microbiota-gut-brain axis: a potential target in the small-molecule compounds and gene therapeutic strategies for Parkinson's disease.

Jiao F, Zhou L, Wu Z Neurol Sci. 2024; 46(2):561-578.

PMID: 39546084 PMC: 11772541. DOI: 10.1007/s10072-024-07878-x.